How Long Does Veoza Take To Work: Complete Efficacy Timeline

Efficacy Timeline: When Does Veoza Start Working?

Clinical trials have demonstrated that Veoza begins to reduce moderate‑to‑severe vasomotor symptoms (hot flashes and night sweats) within the first week of treatment. In the pivotal phase III SKYLIGHT studies, women taking 45 mg once daily reported a statistically significant decrease in hot flash frequency as early as week 1 compared to placebo.

The reduction continues to improve over the following weeks, with the full therapeutic effect typically achieved by week 4. This timeline reflects the time needed for the NK3 receptor blockade to stabilise the hypothalamic thermoregulatory centre and for the body to adjust to the new set‑point.

Absorption Rate: How Quickly Does Veoza Enter the Body?

Fezolinetant is rapidly absorbed after oral administration. The tablet is designed to dissolve in the gastrointestinal tract, and the active substance enters the bloodstream quickly. The time to reach maximum plasma concentration (T_max) is approximately 1–2 hours after taking the dose.

Food does not significantly affect the absorption rate or extent, meaning Veoza can be taken with or without meals without delaying its entry into the body. The absolute bioavailability is around 71%, indicating that most of the dose reaches systemic circulation.

Once absorbed, fezolinetant crosses the blood‑brain barrier efficiently due to its lipophilic properties, allowing it to act directly on NK3 receptors in the hypothalamus.

Peak Concentration: When Does Veoza Reach Maximum Levels?

The peak concentration (C_max) of fezolinetant in the blood is reached within 1–2 hours after ingestion. This coincides with the initial rapid entry into the central nervous system. However, the peak of clinical effect—reduction in hot flashes—lags behind the peak plasma level because receptor occupancy and downstream signalling require some time to modulate the thermoregulatory set‑point.

With once‑daily dosing, steady‑state concentrations are achieved after 5–7 days. At steady state, trough levels remain sufficiently high to maintain continuous NK3 receptor blockade throughout the 24‑hour dosing interval, ensuring consistent symptom control.

Duration in the Body: How Long Does Veoza Stay Active?

The elimination half‑life of fezolinetant is approximately 8–10 hours. This means that after each dose, the concentration in the body decreases by half over that period. Because the dosing interval is 24 hours, once‑daily administration maintains sufficient receptor blockade throughout the day without excessive accumulation.

Even though the drug level declines between doses, the NK3 receptor blockade remains effective for the full 24‑hour period due to the receptor’s slow off‑rate. This allows for sustained control of hot flashes and night sweats with a convenient once‑daily schedule.

After stopping Veoza, the drug’s effects gradually diminish as the concentration falls. Most women will notice a return of vasomotor symptoms within a few days, corresponding to the elimination of the drug.

How Long Does Veoza Take to Leave the Body?

Because fezolinetant has a half‑life of 8–10 hours, it takes about 2–3 days (approximately 5 half‑lives) for the drug to be almost completely eliminated from the body after the last dose. During this time, the concentration drops below the threshold needed for NK3 receptor blockade, and hot flashes may return to pre‑treatment levels.

Fezolinetant is primarily metabolised by the liver enzyme CYP1A2 into inactive metabolites, which are then excreted in urine (80%) and faeces (20%). The clearance is not significantly affected by age, weight, or mild‑to‑moderate renal impairment, but severe hepatic impairment may prolong elimination.

Factors Affecting the Efficacy Timeline

Several individual factors can influence how quickly Veoza works and how long its effects last:

• Concomitant medications: Strong or moderate CYP1A2 inhibitors (e.g., fluvoxamine, enoxacin, mexiletine, ethinyl oestradiol‑containing contraceptives) dramatically increase fezolinetant levels and are contraindicated.
• Liver function: Hepatic impairment reduces clearance, potentially prolonging duration and increasing side effect risk.
• Smoking status: Smoking induces CYP1A2, which may slightly accelerate fezolinetant metabolism, though clinical significance is minor.
• Consistency of dosing: Taking Veoza at the same time each day helps maintain steady‑state levels and predictable efficacy.

Adherence to the prescribed once‑daily regimen is essential for achieving the expected timeline of relief. If doses are missed, steady state may be disrupted, delaying maximal benefit.

Veoza FAQs

Need Veoza with Personalised Timing Advice?

If you are considering Veoza for your menopausal symptoms, our UK‑registered doctors can assess your suitability and provide clear guidance on the expected timeline of relief.

Secure Prescription & Next‑Day Delivery

MHRA‑compliant | GPhC‑registered pharmacy | Discreet packaging | UK‑registered doctors